Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Expands By 115.9%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 117,000 shares, an increase of 115.9% from the September 15th total of 54,200 shares. Based on an average daily volume of 302,300 shares, the short-interest ratio is currently 0.4 days. Currently, 12.5% of the company’s stock are short sold. Currently, 12.5% of the company’s stock are short sold. Based on an average daily volume of 302,300 shares, the short-interest ratio is currently 0.4 days.

Salarius Pharmaceuticals Price Performance

Salarius Pharmaceuticals stock opened at $3.78 on Wednesday. Salarius Pharmaceuticals has a 12-month low of $3.64 and a 12-month high of $108.00. The company has a market capitalization of $1.93 million, a price-to-earnings ratio of -0.09 and a beta of 0.44. The firm’s fifty day moving average price is $4.86 and its 200 day moving average price is $9.15.

Salarius Pharmaceuticals (NASDAQ:SLRX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($33.00) by $32.55.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Salarius Pharmaceuticals to a “sell” rating in a research note on Friday, August 22nd.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.